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Abstract 
 Objectives: To examine the psychometric properties of four widely-used generic 
health status measures in Friedreich’s ataxia (FA), to determine their suitability as 
outcome measures.  
Methods: Fifty-six people with genetically confirmed FA completed the Barthel 
Index (BI), General Health Questionnaire (GHQ-12), EuroQol (EQ-5D) and Medical 
Outcomes Study 36-item Short Form Health Survey (SF-36) via postal survey. Six 
psychometric properties (data quality, scaling assumptions, acceptability, reliability, 
validity and responsiveness) were examined.  
Results: The response rate was 97%. In general, the psychometric properties of 
the four measures satisfied recommended criteria. However, closer examination 
highlighted limitations restricting their use for treatment trials. For example, the BI had 
high missing data, EQ-5D had poor discriminant ability and five SF-36 scales had high 
floor and/or ceiling effects. Most scale scores did not span the entire scale range, had 
means that differed notably from the scale mid-point, and had wide confidence 
intervals. Effect sizes (ES) were small for all four measures raising questions about 
their ability to detect clinically significant change. 
Conclusions: Results highlight the potential limitations of these four scales for 
evaluating health outcomes in FA, and suggest the need for new disease-specific 
patient-based measures of the impact. 
Keywords: Friedreich’s ataxia (FA), health status measures, psychometric, patient-based outcome 
measures 
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Introduction 
 Evaluations of therapeutic interventions should include measurement of patient-
based outcomes.
1
 These outcomes must be measured rigorously if they are to 
influence patient welfare and the expenditure of public funds.
2
 Currently, no disease-
specific patient-based rating scale exists for Friedreich’s ataxia (FA). Commonly used 
ataxia rating scales include the International Cooperative Ataxia Rating Scale (ICARS)
3 
and the International Ataxia Clinical Rating Scale (IACRS).
4
 These are observer rated, 
and quantify the neurological examination of people with ataxia. Neither scale 
incorporates patients' perceptions or evaluates the impact of FA on daily life. A recently 
developed observer-rated scale for FA
5 
also incorporates ADL (activities of daily living) 
assessment. However, none of these three scales were developed using recognised 
psychometric methods of scale construction (item generation, scale formation and 
testing). Perhaps not surprisingly, therefore, the ICARS has recently been shown to 
have limitations to its use in the assessment of FA.
6
 
 
 Apart from one previous study that found disability has an influence on work and 
social activities for people with FA,
7
 a comprehensive literature search generated no 
quality of life studies in FA using standardised measures. Therefore an important first 
step in advancing patient-based outcomes measurement in FDRA is to evaluate the 
potential usefulness of some existing widely used rating scales. As such we conducted 
a postal survey of people with FA using four widely used generic health status 
measures: Barthel Index (BI
8
), General Health Questionnaire (GHQ
9
), EuroQol (EQ-
5D
10
) and Medical Outcomes Study 36-item Short Form Health Survey (SF-36
11
). The 
aim of this study was to evaluate the potential suitability of these measures in treatment 
trials and epidemiological studies in FA. 
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Methods 
Samples 
The sample was 58 people with genetically confirmed FA at the Royal Free 
Hospital. Appropriate ethical committee approval was obtained. Rating scales were 
administered by postal survey in a booklet with some demographic questions. Non-
responders received a single reminder at 8 weeks.
12
 A second postal survey was 
conducted one year after the first survey to assess responsiveness.  
 
Measures 
Four standardised measures were administered: the self-report BI (a measure of 
personal activities of daily living
8,13,14
), the GHQ-12 (a measure of psychological well-
being
9,15
), the EuroQol (EQ-5D Health State and Thermometer
10
) and the SF-36 (a 
measure of health status in 8 scales – Table 1 for description
11
). These scales were 
chosen as they are all widely used generic measures
16-21
 recommended for a range of 
health care settings. 
 
Analyses 
The psychometric properties of the measures were evaluated using standard 
methods that are fully described in previous publications.
22-24
 Six psychometric 
properties were examined: data quality, scaling assumptions, acceptability, reliability 
(internal consistency), convergent and discriminant construct validity and 
responsiveness. 
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Data quality (the extent to which an instrument can be used successfully in a 
clinical setting)
25
 was determined to be high if items had low missing data (<10%), and 
if a high percentage of scale scores were computable for each patient. 
 
Scaling assumptions (the legitimacy to sum item scores without weighting or 
standardisation to generate a total score) were examined by determining whether items 
in each scale had roughly similar response-option frequency distributions, equivalent 
mean and variances, and equivalent item-total correlations (r > 0.30).
26,27
 
 
Acceptability (the targeting of a scale to a sample so that score distributions 
adequately represent the true distribution of health status in the sample
28
) was 
examined to determine that observed scores were well distributed,
29
 mean scores were 
near the scale mid-point
30
 floor and ceiling effects were low, and skewness statistics 
ranged from -1 to +1.
31
 
 
Reliability (the extent to which an instrument is free from random error
32
) was 
examined using internal consistency, using Cronbach's alpha coefficient.
33
 It is 
recommended that alpha >0.80.
34
 We also computed the 95% CI limits around 
individual patient scores as: +/-1.96SEM, where SEM (standard error of measurement) 
= SD x  (1 – alpha). 
 
Validity (the extent to which an instrument measures the concept it purports to 
measure) was examined using convergent and discriminant construct validity.
35
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Correlations between scales were examined to determine the extent to which each 
instrument: 1) measures what it is supposed to measure (convergent construct validity) 
and 2) does not measure what it is not designed to measure (discriminant construct 
validity). Table 1 shows the predicted correlations between measures, based on the 
clinically expected associations between the constructs they purport to measure, using 
broad criteria of: <0.30 = low (L); 0.30 – 0.70 = moderate (M); >0.70 = high (H).  
 
Responsiveness (the ability of an instrument to measure clinically important 
change over time) was examined by scales being administered at Time 1 (T1) and Time 
2 (T2; 12 months later). Responsiveness was determined by calculating effect sizes 
(ES),
36
 as defined as the mean change in score (T1 minus T2) divided by the standard 
deviation of T1 scores. These are interpreted
 
as either small (ES < 0.20), medium (ES = 
0.50) or large (ES > 0.80).
37
 
 
Results 
Samples 
Fifty-six people returned completed questionnaires (response rate 97%). The 
group represented a broad range of adult patients with FA covering the disease 
spectrum from mild to severe. More than half the sample was single, used a wheelchair 
indoors, was not in employment, and was educated past the age of 16 (Table 2).  
 
Measures 
a)  Self-report Barthel Index  
 7 
One item (mobility) had missing data > 10%. Scale scores were computable for 
<90% of the sample, suggesting limited data quality. Item mean scores and standard 
deviations were variable. Scale scores were well-distributed but did not span the entire 
scale range. The mean BI score (16.3 point) was notably lower than the scale mid-point 
(50) although skewness was within the recommended range. The ceiling effect was 
acceptable.
38
 
 
Internal consistency estimates exceeded recommended criteria (>= 0.80). 
However, the 95% CI for individual patient scores were quite wide (16 points) indicating 
limited usefulness for individual-level measurement (Table 3a). The direction and 
pattern of correlations were generally consistent with predictions. However, the 
magnitude of correlations with other physical scales was not as high as predicted (eg BI 
correlated highest with Euroqol health state and years since diagnosis; Table 4). 
 
Change scores indicated minimal worsening of scores, implying worsening 
health between T1 and Time 2, although this was not statistically significant. ESs were 
small, implying low responsiveness (Table 5). 
 
b) GHQ-12 
Missing item data was low and data quality was good (91% computable scale 
scores). Frequency distributions for items were quite symmetrical. Item-total 
correlations (range 0.45 - 0.83) exceeded the criteria of 0.40. Scale scores were well 
distributed but did not span the entire scale range. The mean score (36.1) differed 
somewhat from the mid-point 50, although skewness was acceptable. The ceiling effect 
was minimal (2%). 
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Internal consistency was high. The 95% CI for individual patient scores was less 
than 10 points (Table 3a). Construct validity was supported by the direction, magnitude 
and pattern of correlations with other scales (Table 4).  
 
Change score were significantly lower at Time 2 implying a significant 
improvement over time. However ESs were low, raising the question of limited 
responsiveness (Table 5). 
 
c)  EuroQol (EQ-5D health state and Thermometer) 
Only 80% of the sample completed all the items of the EQ-5D health state. The 
mobility item had 20% missing data suggesting poor data quality. EQ-5D health state 
did not span the entire scale range. Cronbach’s alpha=0.58 for the unweighted items 
indicating limited reliability. Correlations with other scales were in the expected range 
(0.30 - 0.70), except with the SF-36 BP which was low (r=0.13). Many of the 
correlations were in a narrow range (0.29-0.54), indicating limited discriminant ability. 
 
The EuroQoL thermometer was completed by 98% of the sample, was well-
distributed but did not span the entire scale range. The mean score (64.3) was 
somewhat above the scale mid-point (50 points) indicating that the average response 
tended towards better health. No ceiling or floor effect was found, and scores were not 
notably skewed (Table 3a). Correlations with other scales were in the expected range 
(0.30 - 0.70), except for the SF-36 PF which was low (r=0.12). However, many were in 
the range 0.24 – 0.49 indicating limited discriminant ability (Table 4). 
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Change scores indicated very little change in both Thermometer and Health 
State between Time 1 and Time 2. ESs were low. This suggests limited responsiveness 
(Table 5). 
 
d)  SF-36 
Missing data was low. Total scores could be computed for >94% of the sample, 
and frequency distributions for items were quite symmetrical. Item-total scale 
correlations were satisfactory (>0.30) for all scales except PF (0.24 for one item). Five 
out of the 8 scale scores (PF, BP, GHP, VT and MH) were well-distributed but did not 
span the entire scale range. The mean score of the PF, BP, SF, RL-E and MH scales 
differed substantially from the mid-point, by at least 20 points. PF and RL-E were 
outside the skewness range of -1 to +1. GHP, VT and MH scales had small floor and 
ceiling effects. The floor effects of PF, RL-P and RL-E scales were > 20%. The ceiling 
effects of RL-P, BP, SF, and RL-E scales were > 20%. These results suggest that some 
SF-36 scales have limited targeting to this sample (Table 3b). 
 
Internal consistency estimates exceeded the recommended criteria for all scales 
except GHP. The 95% CIs for individual patients were smallest for PF, and widest for 
the RL-E. The correlation between the two psychological scales was substantial (MH 
and RL-E = 0.62). However, the correlations between the physical scales were lower 
than expected: PF and RL-P (0.11), PF and BP (0.08), PF and GHP (0.01), RL-P and 
BP (0.25), RL-P and GHP (0.27), and BP and GHP (0.37). These findings suggest less 
than adequate validity for the physical scales (Table 4). 
 10 
 
Change scores for VT, SF and MH showed statistically non-significant 
improvement between Time 1 and Time 2. Change scores for RL-E, BP, and PF 
showed statistically non-significant worsening between Time 1 and Time 2. Change 
scores for GHP showed statistically significant worsening of scores. The scores for RL-
P did not change between Time 1 and Time 2. For all scales, ESs were small, implying 
limited responsiveness (Table 6). 
 
Discussion 
 This study examined the suitability of four widely used generic scales for use 
as outcome measures in FA research. In general, they satisfied basic criteria. As such 
we are able to make inferences about patients’ perceptions of the impact of FA. It has a 
substantial impact on physical function, psychological well-being, general health 
perceptions, vitality, and overall quality of life. In addition, a comparison with SF-36 data 
in Multiple Sclerosis (MS) patients,
39
 indicate that the physical impact in FA is greater. 
However, larger samples with age, sex and disability-matched comparisons with MS 
and other disease groups are required to make detailed and specific comparisons. 
 
 Although scales satisfied basic psychometric criteria, closer examinations 
highlight limitations that restrict their use in treatment trials. Most scales were not 
completed by the whole sample. BI Mobility and EQ5D had the highest missing data. 
This has implications for dropout rates, which in turn impact on the interpretation of 
studies. Unfortunately, our data do not provide an explanation for this finding. As the BI 
does not have a category for mobility without aid a proportion of these patients may 
have felt unable to answer this question. The ambiguity of response options is another 
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possible, but unlikely, reason. High missing data implies an item is of limited relevance 
and that it should be considered for removal. However, in this case, we would 
recommend qualitative work to uncover the true cause as mobility is an important 
aspect of disabling neurological disorders. 
 
Five of the eight SF-36 scales had floor and/or ceiling effects. This suggests poor 
scale-to-sample targeting and has potential implications for detecting change in 
treatment trials. High floor or ceiling effects at baseline almost certainly underestimate 
change over time, and due to treatments. Thus small but clinically meaningful changes 
may go undetected. Floor and ceiling effects may also attenuate correlations between 
measures, as correlations are sensitive to scale ranges. This may explain why some of 
the expected correlations (Table 1) were not observed.  
 
The mean score of the majority of scales (BI, GHQ-12, EuroQol, SF-36 PF, BP, 
SF, RL-E and MH) differed notably from the scale mid-point, suggesting limited 
targeting in this sample. The wide confidence intervals observed suggest that the 
measures are not applicable for individual patient monitoring, supporting previous 
work.
38
 In addition, correlations between the physical scales and other SF-36 scale 
were lower than expected, suggesting limited validity. An alternative explanation is this 
may reflect the way FA patients view their illness as a unique set of physical features of 
FA, but to clarify this requires reliable and valid measures of each domain. 
 
 Effect sizes for all four measures were small. FA is a progressive disorder, so 
we might expect deterioration, at least in physical function. Low ESs imply limited 
responsiveness, which is an important consideration for treatment trials as they may 
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not be sensitive to detect small but clinically important changes. However, further 
responsiveness studies are needed that compare changes in scores to an external 
criterion of change, such as a transition question. Furthermore, assessment of change 
in FA is complicated by two factors: 1) the diverse nature of FA may mean that different 
functions may be affected at different stages of the disease and 2) the slow disease 
progression means that one year or less may be too short to detect any change in 
disease progression. This has implications for evaluating treatments that attempt to 
slow down the natural history of FA and studies may need to be over a long period of 
time if we are to detect true differences. 
 
 There are several limitations to the study. First, our sample size was small. 
However, FA is relatively rare, and sixty patients represents one of the largest studies 
of its type. Also, there is evidence to suggest that useful reliability and validity estimates 
can be obtained from small (even non representative) samples,
40,41
 and that Cronbach’s 
alpha is  considered a conservative estimate of reliability.
42
 Second, the sample 
representativeness is unknown as it  may have been skewed towards the advanced 
stages of the disease, and patients under 18 years were not represented. Third, this 
study only examined a few of the many available scales. However, the inherent 
physical and mental fatigability of people with FA, and time taken to complete some of 
these scales, limits the number of instruments that can be administered at one time. 
Also, additional measures may have led to them being completed over several days, 
adding the complication of day-to-day variability, which is known to be substantial in 
FA. It would be valuable to form a UK register of people with FA, identify a list of 
potentially valuable measures, and systematically evaluate small groups using these 
measures over time. This would underpin evidence-based measurement in FA. A 
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fourth limitation is that we did not compare normative data for each scale. However, the 
primary aim of this paper was to psychometrically evaluate each scale, which is a 
prerequisite for meaningful comparisons. The problems uncovered may suggest that 
any comparison would be limited. In addition, there is no normative data available for 
the BI and GHQ-12. Finally, we did not determine whether patients were able to self-
complete each questionnaire, or if they required assistance, and therefore do not know 
how this may have affected our findings. 
 
Despite these limitations, this study supports the use of self-report 
questionnaires in FA to capture aspects of outcome not captured by objective 
measures, and providing a clearer picture of the wider impact of FA. Although the 
responsiveness of such measures is in question, the development of a new scale 
tailored specifically to FA patients may address such a shortfall. In real terms, the 
psychometric shortfalls of each measure question their appropriateness in cross-
sectional descriptive studies (due to poor targeting), longitudinal studies (due to 
potential problems of assessing clinical change) and individual patient monitoring (due 
to wide confidence intervals around scale scores).  
 
 This study aimed to evaluate the potential for existing generic scales to measure 
the impact of FA in studies. This evidence has been thus far lacking. If these measures 
had passed this first hurdle, which they did not, the next step would have been to carry 
out careful and meaningful cross sectional and longitudinal examinations of the 
relationship between quality of life and disease severity. The limitations of these four 
scales suggest that new disease-specific patient-based measures of the impact of FA 
are needed if accurate evaluations of its natural history are required, and if unique 
 14 
studies of the relationships between molecular genetics, clinical manifestations and 
health status are to be undertaken.  
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Table 1. Correlations between measures predicted a priori* 
Instrument Scale / 
dimension 
/ variable 
Barthel GHQ-12 
 
EuroQol- 
Thermom
eter 
EuroQol- 
Health 
State 
SF-36 
PF 
SF-36 
RL-P 
SF-36 
BP 
SF-36 
GHP 
SF-36 
VT 
SF-36 
SF 
SF-36 
RL-E 
SF-36 
MH 
GHQ-12  L - - - - - - - - - - - 
EuroQol Thermometer M M     - - - - - - - - - - 
 Health state H L M - - - - - - - - - 
SF-36 
1
  PF H L M M - - - - - - - - 
 RL-P H L M M H - - - - - - - 
 BP M M M M M M - - - - - - 
 GHP L M M M M M M - - - - - 
 VT L M M M M M M M - - - - 
 SF L M M M M M M M M   -   -   - 
 RL-E L H M M L L L M M   M   -   - 
 MH L H M M L L L M M   M   H   - 
  
            
Demographic 
variables 
Age L L L L L L L L L   L   L   L 
 Sex L L L L L L L L L   L   L   L 
 Years since 
diagnosis 
M L/M M M M M L L/M L/M  L/M  L/M  L/M 
*SF-36 scales are: physical functioning (PF), role limitations [physical problems] (RL-P), bodily pain (BP), general health perception 
(GHP), vitality (VT), social functioning (SF), role limitations [emotional problems] (RL-E), and mental health (MH). 
 
 
                                                 
1
 Medical Outcomes Study 36-item Short Form Health Survey: high scores = better health. 
L = < 0.30; M = 0.30 -0.70; H = > 0.70 
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Table 2 Sample characteristics 
 
Characteristics  
Age (n = 56)   
 mean (SD)  31.0 (8.6)  
 range 18 - 57 
  
Sex (n = 56)  
 % female 57.1 
  
Yrs since FA diagnosed (n = 55)  
 mean (SD)  13.3 (8.5)  
 range 1 - 32 
  
Yrs since FA started (n = 49)  
 mean (SD)  18.1 (8.4) 
 range 4 - 38 
  
Ethnicity (n = 56) 94.6 
 % white  
  
Employment status (n=54) %  
 Employed/self employed 40.8 
 Retired due to FA 25.9 
 Retired for other reasons 1.9 
 Unemployed 18.5 
 Student 13.0 
  
Education (n = 56) %  
 Educated after minimum school leaving age 64.3 
 Degree / equivalent qualification 25.0 
  
Marital status (n=56) %  
 Single 58.9 
 Married 21.4 
 Divorced 5.4 
 With a partner 14.3 
  
Mobility indoors (n = 56) %  
 Walks unaided 14.3 
 Walks with an aid 30.4 
 Wheelchair user 55.4 
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Table 3a Data quality, scaling assumptions, acceptability and reliability of health status 
measures  
 
 Health status measures 
 Barthel GHQ-12 EuroQol 
Thermometer 
EuroQol 
Health State 
N  47  51  55  45  
Data quality     
Item missing data 
% 
0-14.3 1.8-3.6 1.8 0-19.6 
Computable 
scale scores% 
84% 91% 98% 80% 
     
Scaling 
assumptions 
    
Item mean 
scores 
0.43-2.34 1.78-2.31 N/A N/A 
Item SD 0.31-1.04 0.37-0.92 N/A N/A 
Item-total 
correlation 
0.26-0.84 0.45-0.83 N/A N/A 
     
Acceptability     
Scale range  0-100 0-100 0-100  -0.59-1.00 
Score range 10-100 0-78 20-95 -0.09-1.00 
Mean score (SD) 67.3 (23.6) 36.1 (16.9) 64.3 (19.1) 0.53 (0.30) 
Floor/ceiling % 0/8.5 0/2.0 0/0 0/2.2 
Skewness
2
 -0.580 0.678 -0.748 -0.902 
     
Reliability     
Alpha 0.87 0.92 N/A 0.58 
     
SEM
3 8.5 4.8 N/A N/A 
95% CI
4 
16.7 9.4 N/A N/A 
 
                                                 
2
 It is recommended that skewness statistic ranges from -1 to +1 
3
 Standard Error of Measurement = SD x  1 - alpha 
4
 95% Confidence Interval =  1.96 x SEM 
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Table 3b Data quality, scaling assumptions, acceptability and reliability of health status measures (SF-36) 
 
 SF-36 Dimensions 
 PF RL-P BP GHP VT SF RL-E MH 
N  54 55  56 55 55 56 53  55  
         
Data quality         
Item missing data 
% 
1.8-5.4 0-1.8 0-3.6 0-1.8 1.8-3.6 0 3.6-5.4 1.8 
Range 
computable  
scale scores% 
96.4 98.2 100 98.2 98.2 100 94.6 98.2 
         
Scaling 
assumptions 
        
Item mean 
scores 
1.14-2.10 1.42-1.65 4.84-4.99 1.93-3.67 3.11-3.78 3.75-3.96 1.68-1.81 3.70-5.02 
Item SD 0.45-0.78 0.48-0.51 1.19-1.19 1.04-1.46 1.26-1.33 1.15-1.21 0.40-0.47 1.11-1.41 
Item-total 
correlation 
0.24-0.87 0.60-0.85 0.81 0.44-0.69 0.70-0.80 0.69 0.56-0.70 0.61-0.88 
         
Acceptability         
Scale range 0-100 0-100 0-100 0-100 0-100 0-100 0-100 0-100 
Score range 0-90 0-100 22-100 5-100 0-85 0-100 0-100 24-100 
Mean score (SD) 21.7 (23.7) 50.9 
(42.5) 
78.3 (22.6) 46.8 (23.4) 49.8 (22.3) 71.4 (27.3) 73.0 (37.6) 67.2 (21.3) 
Floor/ceiling % 20.4/0 27.3/36.4 0/39.3 0/1.8 1.8/0 1.8/28.6 15.1/58.5 0/1.8 
Skewness
5
 1.401 0.059 -0.814 0.217 -0.474 -0.885 -1.056 -0.404 
         
Reliability         
Alpha 0.92 0.88 0.90 0.79 0.88 0.82 0.80 0.89 
         
SEM
6 6.7 14.7 7.1 10.7 7.7 11.6 16.8 7.1 
95% CI
7 
 13.1  28.9  14.0  21.0  15.1  22.7  33.0  13.8 
                                                 
5
 It is recommended that skewness statistic ranges from -1 to +1 
6
 Standard Error of Measurement = SD x  1 - alpha 
7
 95% Confidence Interval =  1.96 x SEM 
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Table 4 Convergent and discriminant construct validity of the health status measures 
Instrument Scale / 
dimension 
/ variable 
Barthel GHQ-12 
 
EuroQol- 
Thermom
eter 
EuroQol- 
Health 
State 
SF-36 
PF 
SF-36 
RL-P 
SF-36 
BP 
SF-36 
GHP 
SF-36 
VT 
SF-36 
SF 
SF-36 
RL-E 
SF-36 
MH 
GHQ-12  -0.03 - - - - - - - - - - - 
EuroQol Thermometer 0.08 -0.38     - - - - - - - - - - 
 Health state 0.70 -0.28 0.39 - - - - - - - - - 
SF-36 
8
  PF 0.55 -0.07 0.12 0.54 - - - - - - - - 
 RL-P 0.14 -0.41 0.26 0.29 0.11 - - - - - - - 
 BP -0.06 -0.31 0.24 0.13 -0.08 0.25 - - - - - - 
 GHP -0.00 -0.39 0.43 0.30 0.01 0.27 0.37 - - - - - 
 VT 0.06 -0.65 0.49 0.48 0.23 0.39 0.42 0.38 - - - - 
 SF 0.00 -0.60 0.49 0.43 0.11 0.45 0.32 0.42 0.61   -   -   - 
 RL-E 0.21 -0.57 0.38 0.29 -0.01 0.36 0.12 0.39 0.41 0.53   -   - 
 MH 0.09 -0.75 0.32 0.35 0.14 0.22 0.24 0.40 0.59 0.57 0.62   - 
              
Demographic 
variables 
Age -0.22 -0.17 -0.01 0.02 -0.07 -0.13 0.00 0.16 0.30 0.11 0.06 0.31 
 Sex 0.11 -0.08 0.22 0.26 -0.00 0.24 0.05 0.35 0.10 0.32 0.31 0.04 
 Years since 
diagnosis 
-0.67 -0.11 -0.09 -0.47 -0.48 -0.15 0.13 0.14 0.18 0.02 -0.05 0.07 
 
                                                 
1
 Medical Outcomes Study 36-item Short Form Health Survey: high scores = better health. 
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Table 5  
Barthel Index, GHQ-12, EurQol-5D (Transformed 0-100) 
Responsiveness (T-Test and Effect Size) 
 
 Measures 
 Barthel Index GHQ-12 EuroQol 
Thermometer 
EuroQol 
Health State 
N 43 43 41 36 
Mean score time 1 (SD) 69.8 (20.1) 36.9 (18.4) 63.4 (18.8) 0.58 (0.25) 
Mean score time 2 (SD) 68.0 (18.5) 32.8 (15.7) 65.3 (19.1) 0.55 (0.25) 
Time 1 – Time 2 difference (SD) 1.74 (8.16) 4.13 (13.20) -1.88 (16.6) 0.03 (0.19) 
t-test 1.40 2.05 -0.72 1.05 
p 0.17 0.05 0.47 0.30 
Effect size 0.09 0.23 0.10 0.13 
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Table 6  
SF-36 (0-100) 
Responsiveness (T-Test and Effect Size) 
 
 SF-36 Dimensions 
 RL-E RL-P BP VT GHP SF PF MH 
N 42 43 43 42 43 43 42 42 
Mean score time 1  
(SD) 
76.2 
(34.8) 
51.2 
(41.9) 
79.0 
(21.7) 
47.9 
(22.8) 
48.5 
(23.8) 
69.5 
(29.4) 
22.1 
(22.9) 
66.5 
(21.6) 
Mean score time 2  
(SD) 
75.4 
(36.9) 
51.2 
(35.8) 
74.0 
(25.2) 
50.0 
(21.3) 
42.8 
(24.6) 
75.6 
(25.0) 
20.1 
(22.8) 
66.7 
(23.6) 
Time 1 – Time 2 
difference (SD) 
0.79 
(34.9) 
0.00 
(42.6) 
5.02 
(21.5) 
-2.02 
(18.5) 
5.67 
(16.8) 
-6.11 
(29.9) 
2.02 
(19.6) 
-0.21 
(15.5) 
t-test  0.15 0.00 1.54 -0.71 2.22 -1.34 0.67 -0.09 
p 0.88 1.00 0.13 0.48 0.03 0.19 0.52 0.93 
Effect size 0.01 0.00 0.06 0.04 0.12 0.09 0.09 0.01 
 
